{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018884","form_type":"8-K","ticker":"AIMD","cik":"0001014763","company_name":"Ainos, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.887532+00:00","generated_at":"2026-06-02T01:44:19.228198+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ainos Q1 revenue down 58% YoY to $20.7K; net loss widens to $3.3M; secures $9M convertible note","bullets":["Revenue of $20,729 in Q1 2024, down 58% from $49,164 in Q1 2023, due to pivot from COVID-19 test kits.","Net loss attributable to common stockholders was $3.3M, compared to $2.5M in prior year.","Cash and cash equivalents $1.03M as of Mar 31, 2024, down from $1.89M at Dec 31, 2023.","Raised $9M convertible note post-quarter (6% interest, convertible at $4.50/sh) from existing shareholder.","Submitted clinical hold response to FDA for VELDONA Phase II trial for mild COVID-19."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018884","json":"https://secwatch.observer/filing/0001493152-24-018884.json","markdown":"https://secwatch.observer/filing/0001493152-24-018884.md","text":"https://secwatch.observer/filing/0001493152-24-018884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1014763/000149315224018884/0001493152-24-018884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1014763/000149315224018884/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:44:19.228198+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21f193026258d080061525d916cfb6a51280b5ee","claim":"Ainos, Inc. reported first quarter ended March 31, 2024 results: revenue US$20,729, net income US$3,314,810.","evidence_excerpt":"Revenues were US$20,729 in the first quarter of 2024, compared to US$49,164 in the same period of 2023, reflecting the Company’s cessation of sales of its COVID-19 antigen rapid test kits during the first quarter of 2024 after a strategic pivot shift.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1014763/000149315224018884/0001493152-24-018884-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"US$20,729"},{"label":"Net income","value":"US$3,314,810"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}